Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.35 |
| ▸ | CNR1 | P21554 | 5/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19274420 | 0.94 | CNR2 (0.33) | CNR2CNR1 | |
| SCHEMBL18516838 | 0.88 | CNR2 (0.36) | CNR2CNR1ESR1ESR2AR | |
| SCHEMBL20243855 | 0.86 | ESR1 (0.39) | CNR2CNR1ESR1ESR2AR | |
| SCHEMBL19251066 | 0.86 | HCAR2 (0.32) | CNR2CNR1ESR1ESR2AR | |
| SCHEMBL19963868 | 0.86 | CNR2 (0.33) | CNR2CNR1 | |
| SCHEMBL25006036 | 0.86 | CNR1 (0.31) | CNR2CNR1 | |
| SCHEMBL19251107 | 0.86 | CHRNB2 (0.35) | CNR2CNR1 | |
| SCHEMBL19251089 | 0.83 | CHRNB2 (0.39) | CNR2CNR1 | |
| SCHEMBL18381788 | 0.82 | CYP19A1 (0.40) | CNR2CNR1ESR1ESR2 | |
| SCHEMBL19251665 | 0.82 | CYP11B2 (0.39) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334893-A1 | Isoxazole Analogs as FXR Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334893-A1 | Isoxazole Analogs as FXR Agonists and Methods of Use Thereof | FXR1, SLC10A1, NR1H4 | CNR2 564/4885CNR1 486/4885ESR1 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.